Skip to content
Clinical Trials – home
AustriaBack to Austria

Clinical trials in Graz – page 25

413 clinical trials in Graz, Austria across 3 research sites. Every trial is listed in the EU Clinical Trials Register and updated daily.

Graz at a glance
413
clinical trials
  • Research sites3
Type of trial
Recruitment status
Quick filters

413 trials in Graz

Open in trial search

Study on the Effects of TAK-341 for Patients with Multiple System Atrophy

Registered drug
Countries:AustriaAustria
  • Participants:18–64 years · 65+ years
  • Substances:Saline
  • Sponsor:Takeda Development Center Americas Inc.

Breast cancer

Not recruiting

Study of Camizestrant and CDK4/6 Inhibitor for Patients with Advanced Breast Cancer with ESR1 Mutation

Registered drug
Countries:AustriaAustria
  • Participants:18–64 years · 65+ years
  • Substances:Abemaciclib
  • Sponsor:AstraZeneca AB

Study of AB-1002 gene therapy given through coronary arteries in adults with severe (NYHA Class III) heart failure caused by non-ischemic cardiomyopathy

Investigational
Countries:AustriaAustria
  • Participants:18–64 years · 65+ years
  • Substances:AB-1002
  • Sponsor:Askbio Inc.

Study of iptacopan effectiveness in achieving remission in patients with active ANCA-associated vasculitis

Investigational
Countries:AustriaAustria
  • Participants:18–64 years · 65+ years
  • Substances:Iptacopan
  • Sponsor:Novartis Pharma AG

Cardiac amyloidosis

Not recruiting

Study on the Effectiveness and Safety of Eplontersen for Patients with Transthyretin-Mediated Amyloid Cardiomyopathy (ATTR-CM)

Investigational
Countries:AustriaAustria
  • Participants:18–64 years · 65+ years
  • Substances:Eplontersen
  • Sponsor:Ionis Pharmaceuticals Inc.

Study of Aflibercept 8mg for Patients with Neovascular Age-Related Macular Degeneration Previously Treated with Faricimab and Aflibercept 2mg

Registered drugNo placebo
Countries:AustriaAustria
  • Participants:18–64 years · 65+ years
  • Substances:Aflibercept
  • Sponsor:Medical University Of Graz

Study on the Effects of ARO-APOC3 for Adults with Familial Chylomicronemia Syndrome

Investigational
Countries:AustriaAustria
  • Participants:18–64 years · 65+ years
  • Substances:Synthetic Double-Stranded Sirna Oligonucleotide Directed Against Apolipoprotein C-Iii Mrna And Covalently Linked To A Ligand Containing Three N-Acetylgalactosamine Residues
  • Sponsor:Arrowhead Pharmaceuticals Inc.

Malignant melanoma

Not recruiting

Study on Fianlimab and Cemiplimab for Adults with Resectable Stage III and IV Melanoma

Registered drug
Countries:AustriaAustria
  • Participants:18–64 years · 65+ years
  • Substances:Cemiplimab
  • Sponsor:Regeneron Pharmaceuticals Inc.

Study on the Effect of Extending Imatinib Treatment from Three to Five Years for Patients with High-Risk Gastrointestinal Stromal Tumor (GIST)

Registered drugNo placebo
Countries:AustriaAustria
  • Participants:18–64 years · 65+ years
  • Substances:Imatinib
  • Sponsor:Region Skane

Adenocarcinoma gastric+1

Not recruiting

Study Comparing Ramucirumab with Irinotecan, Leucovorin, and 5-FU or Paclitaxel for Patients with Advanced Stomach or Gastroesophageal Cancer After Previous Chemotherapy

Registered drugNo placebo
Countries:AustriaAustria
  • Participants:18–64 years · 65+ years
  • Substances:Calcium Folinate
  • Sponsor:Frankfurter Institut Fuer Klinische Krebsforschung IKF GmbH

Hidradenitis

Not recruiting

Study of lutikizumab compared to placebo in adults and adolescents (age 12 and older) with moderate to severe Hidradenitis Suppurativa

Investigational
Countries:AustriaAustria
  • Participants:0–17 years · 18–64 years · 65+ years
  • Substances:Lutikizumab
  • Sponsor:AbbVie Deutschland GmbH & Co. KG
Countries:AustriaAustria
  • Participants:18–64 years · 65+ years
  • Substances:Riociguat
  • Sponsor:Thoraxklinik Heidelberg gGmbH

Other cities in Austria

The busiest research cities in the country

All 47 cities in Austria

Clinical research in Graz

What the registry says about research in the country

01 Oncology Research

Innovative trials exploring treatments for various cancers, including bladder cancer, breast cancer, and gastric cancer. Studies focus on combination therapies and novel treatment approaches.

  • Early-stage bladder cancer treatment trials
  • HER2-positive cancer therapies
  • Pediatric liver cancer studies

Research emphasizes immunotherapy combinations and targeted treatments for better patient outcomes.

02 Metabolic Disorders

Clinical research focusing on diabetes management and obesity treatments. Studies include innovative approaches to blood glucose control and cardiovascular safety assessments.

  • Type 1 and Type 2 diabetes treatments
  • Obesity management therapies
  • Cardiovascular risk assessment

Investigations aim to improve treatment options and patient care strategies.

03 Inflammatory Conditions

Studies addressing various inflammatory diseases, including chronic rhinosinusitis and Crohn's disease. Research focuses on novel therapeutic approaches and disease management.

  • Nasal polyp treatments
  • Autoimmune disease therapies
  • Inflammatory response management

Trials evaluate both established and experimental treatment options.

Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Tell us about your condition – we search every trial in Europe and connect you with the right site.